

ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive/ efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity

Kirsten Richter¹, Nicole Egli¹, Laetitia Petersen¹, Patrizia Murer¹, Andreas Katopodis¹, Christoph Huber¹

Background



Results




PBMCs were stimulated with 10 nM ANV419, IL-2, IL-15 or left unstimulated. Stat5 phosphorylation in NK and CD8 T cells was measured by flow cytometry at the indicated time points.

ESMO Annual Meeting 2022


A) In vitro NK cell killing of HER2 expressing HCC1954 cells in presence of 10nM ANV419 and/or 0.07 nM Herceptin (trastuzumab). B) Tumor growth using BALB/c Nude mice in a Her2-expressing NCI-N87 xenograft mouse model. The mice (n=10) were treated with 7.5 mg/kg Herceptin 2QW and/or 220 µg/kg ANV419 QW.

¹Anaveon, Basel Switzerland

SNP F158V



was normalized to Staurosporine control treated target cells.



BALB/c mice (n=12) were injected s.c. with H22 hepatic carcinoma cells on day 0 and treated A) vehicle, 0.2 mg/kg ANV419 i.v. 2QW, 10 mg/kg anti-PD1 (clone RMP1-14) i.p. 2QW or a combination of ANV419 and anti-PD1. B) vehicle, 3 doses of 0.2 mg/kg ANV419 i.v. 2QW, 3 doses of 1 mg/kg anti-CTLA4 (clone 9D9) i.p. 2QW or a combination of ANV419 and anti-CTLA4.

Conclusions

- data

ANA EON

ANV419 amplifies NK cell mediated killing independent of FcyR3a

The data presented here support the initiation of clinic phase 2 studies assessing ANV419 treatment in indications in which NK and CD8 T cells are involved in tumor resolution as monotherapy and in combination with ADCC inducing treatments or checkpoint inhibitors

Please visit poster 749P for more information on our phase



Poster 39P